C4 Therapeutics, Inc. Stock Price, News & Analysis

C4 Therapeutics, Inc. (Nasdaq: CCCC), a clinical-stage biopharmaceutical company, announced its participation in a fireside chat at the Stifel 2023 Virtual Targeted Oncology Days. The event is scheduled for April 26, 2023, at 11:00 AM ET. C4T is focused on advancing targeted protein degradation science to develop small-molecule medicines aimed at transforming disease treatment. Through its innovative TORPEDO® platform, C4T is designing therapies that leverage the body’s protein recycling system to degrade disease-causing proteins, addressing challenges like drug resistance. A live webcast of the chat will be available on C4T's website, along with an archived replay for 30 days post-event.

C4 Therapeutics (Nasdaq: CCCC) reported a revenue decline to $31.1 million for the year ended December 31, 2022, down from $45.8 million in 2021, primarily due to a one-time recognition in the prior year. R&D expenses increased to $117.8 million from $94.7 million, driven by clinical activities. The company posted a net loss of $128.2 million and net loss per share of $2.62, compared to $83.9 million and $1.82, respectively. Despite the financial challenges, C4T anticipates a cash runway until the end of 2024 and is focusing on advancing multiple clinical trials, with important data expected in 2H 2023.

C4 Therapeutics, Inc. (Nasdaq: CCCC), a clinical-stage biopharmaceutical firm, announced its participation in two virtual conferences in February 2023. The SVB Securities Global Biopharma Conference will feature a fireside chat on February 15 at 3:00 PM ET, while a panel discussion titled Key Targets for Targeted Protein Degradation in Oncology is scheduled for February 21 at 12:00 PM ET during the 2023 Wells Fargo Targeted Protein Degradation Summit. Live webcasts will be accessible on the company’s website, with archived replays available for 30 days. C4T is focused on targeted protein degradation to develop innovative therapies for challenging diseases.

C4 Therapeutics, Inc. (Nasdaq: CCCC) announced the first patient has been dosed in its Phase 1/2 clinical trial for CFT1946, a targeted therapy for BRAF V600 mutant solid tumors. This marks the first degrader to enter clinical development aimed at BRAF-driven cancers, generally treated with limited options once resistance develops. Early studies indicate CFT1946 may offer deeper and more durable efficacy than current BRAF inhibitors. The trial will assess safety and effectiveness, progressing to evaluate CFT1946 both alone and with trametinib in advanced phases. This initiative expands C4T's oncology programs via its proprietary TORPEDO® platform.

C4 Therapeutics (Nasdaq: CCCC) reports continued progress in its oncology trials, with key updates expected in 2023. The company is advancing CFT7455 and CFT8634, focusing on multiple myeloma and synovial sarcoma treatments. Phase 1 dose escalation data for both drugs will be shared in the second half of 2023. Additionally, CFT1946 targeting BRAF-V600 mutations has initiated trials. As of September 30, 2022, C4T holds $366 million in cash, enough to fund operations into 2024. A presentation at the J.P. Morgan Healthcare Conference is also scheduled.

C4 Therapeutics (Nasdaq: CCCC), a clinical-stage biopharmaceutical company, announced its participation in the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 10:30 am PST (1:30 pm EST) in San Francisco. The event will be accessible via a live webcast on the company’s website, with a replay available for two weeks afterward. C4T focuses on targeted protein degradation to develop innovative medicines for difficult-to-treat diseases, leveraging its TORPEDO® platform to enhance patient outcomes.